Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Immunotech BiopharmHKSE:06978 +5.00%20 3-Year ROIIC % is -506.04 as of Dec. 2025. GuruFocus rates HKSE:06978 with a GF Score™ of 20/100. The stock has 3 warning signs investors should review. Among 1,310 Biotechnology companies, Immunotech Biopharm ranks worse than 89.47% on this metric.
3-Year Return on Invested Incremental Capital (3-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 3-year.
Immunotech Biopharm's 3-Year ROIIC % for the quarter that ended in Dec. 2025 was -506.04%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
The industry rank for Immunotech Biopharm's 3-Year ROIIC % or its related term are showing as below:
HKSE:06978's 3-Year ROIIC % is ranked worse than 89.47% of 1310
companies
in the Biotechnology industry
Industry Median: -5.595
vs HKSE:06978: -506.04
Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.
High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
Be Aware
It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.
Immunotech Biopharm 3-Year ROIIC % Related Terms
Immunotech Biopharm 3-Year ROIIC % Historical Data
* Premium members only.
The historical data trend for Immunotech Biopharm's 3-Year ROIIC % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HKSE:06978 vs VRTX, REGN, MRNA: 3-Year ROIIC % Comparison
For the Biotechnology subindustry, Immunotech Biopharm's 3-Year ROIIC %, along with its competitors' market caps and 3-Year ROIIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Immunotech Biopharm 3-Year ROIIC % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Immunotech Biopharm's 3-Year ROIIC % distribution charts can be found below:
* The bar in red indicates where Immunotech Biopharm's 3-Year ROIIC % falls into.
Immunotech Biopharm's 3-Year ROIIC % for the quarter that ended in Dec. 2025 is calculated as:
3-Year ROIIC %
=
3-Year Incremental Net Operating Profit After Taxes (NOPAT)**
/
3-Year Incremental Invested Capital**
=
( -172.113 (Dec. 2025) - -300.206 (Dec. 2022) )
/
( 888.265 (Dec. 2025) - 913.578 (Dec. 2022) )
=
128.093
/
-25.313
=
-506.04%***
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** Annual data of NOPAT and Invested Capital was used to calculate 3-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
Immunotech Biopharm (HKSE:06978) has a 3-Year ROIIC % of -506.04 as of Dec. 2025. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Immunotech Biopharm and its competitors. According to the industry distribution chart, Immunotech Biopharm ranks #1172 out of 1310 companies in the Biotechnology industry, placing it in the top 89.5%.
Is Immunotech Biopharm's 3-Year ROIIC % too high?
Immunotech Biopharm's current 3-Year ROIIC % is -506.04. Based on the distribution chart, Immunotech Biopharm ranks #1172 out of 1310 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Immunotech Biopharm has a GF Score™ of 20/100, reflecting its overall financial health beyond just this single metric.
How does Immunotech Biopharm's 3-Year ROIIC % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Immunotech Biopharm ranks #1172 out of 1310 companies for 3-Year ROIIC %. This places Immunotech Biopharm in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year ROIIC % for a Biotechnology company?
A good 3-Year ROIIC % depends on the Biotechnology industry context. However, 3-Year ROIIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year ROIIC % mean?
A high 3-Year ROIIC % can signal that a stock is expensive relative to its fundamentals. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Immunotech Biopharm and its competitors. Immunotech Biopharm's current 3-Year ROIIC % is -506.04. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Immunotech Biopharm stock overvalued right now?
Immunotech Biopharm (HKSE:06978) has a current 3-Year ROIIC % of -506.04. The current 3-Year ROIIC % is -506.04. Immunotech Biopharm's overall GF Score™ is 20/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year ROIIC % calculated?
3-Year ROIIC % is calculated from a company's financial statements. For Immunotech Biopharm (HKSE:06978), the current 3-Year ROIIC % is -506.04 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Immunotech Biopharm Ltd is a cellular immunotherapy biopharmaceutical company in China. The company is focused on the research, development, and commercialization of T-cell immunotherapy. Its product EAL is a multi-target cellular immunotherapy product for the treatment of various types of cancer. Its product pipeline features classes of cellular immunotherapy products, including both non-genetically modified and genetically modified products, as well as both multi-target and single-target products. Its other products include the CAR-T cell series and the TCR-T cell series.
20GF Score
Get the complete analysis for HKSE:06978
3-Year ROIIC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:06978 has been successfully added to your 
